Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Melanoma 56Carcinoma, Non-Small-Cell Lung 56Carcinoma, Renal Cell 34Neoplasms 33Neoplasm Metastasis 29Colorectal Neoplasms 23Squamous Cell Carcinoma of Head and Neck 22Pancreatic Neoplasms 22Carcinoma, Hepatocellular 21Carcinoma, Transitional Cell 18Lung Neoplasms 17Glioblastoma 15Ovarian Neoplasms 14Triple Negative Breast Neoplasms 13Breast Neoplasms 13Urinary Bladder Neoplasms 11Stomach Neoplasms 11Head and Neck Neoplasms 10Uveal Melanoma 9Recurrence 8Myelodysplastic Syndromes 8Lymphoma 8Leukemia, Myeloid, Acute 8Advanced Cancer 8Small Cell Lung Carcinoma 7Multiple Myeloma 7Kidney Neoplasms 7Hodgkin Disease 7Hematologic Neoplasms 7Glioma 7

Interventions

Nivolumab 2radium Ra 223 dichloride 1poly ICLC 1fludarabine phosphate 1fludarabine 1darolutamide 1cabozantinib 1bempegaldesleukin 1Radium-223 1Radiosurgery 1Pluvicto 1Cyclophosphamide 1Blood Specimen Collection 1Abiraterone Acetate 1177Lu-EB-PSMA-617 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Metastatic Castration-resistant Prostate Cancer × Nivolumab × Clear all
NCT04109729 2026-06-01

Rad2Nivo

University of Utah

Phase 1 Active not recruiting
39 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT03835533 2024-04-12

PORTER

Parker Institute for Cancer Immunotherapy

Phase 1 Completed
43 enrolled 19 charts
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡